Table 4 Clinical trials-thalidomide (Transplant Ineligible)
From: Thalidomide and its analogues in the treatment of Multiple Myeloma
Author | Regimen(s) | Type of clinical trial | No. of pts | Best responses (>PR) | CR, nCR, VGPR | PFS/TTP/OS (months) | Reference |
|---|---|---|---|---|---|---|---|
Palumbo et al | MPT+T maintenance vs. MP | Phase III | 255 | 76% vs 47.6% | CR:15.5% vs. 2.2% | OS:45 vs. 47.6 PPS:21.8 vs. 14.5 | Blood 2008 |
Facon et al | MPT vs MP vs. HDT/ASCT | Phase III | 427 | 89% vs 37% vs 83% | CR:13% vs. 2% vs. 18% VGPR:47% vs. 7% vs. 43% | OS:51.6 vs. 33.2 vs. 38.3 | Lancet 2007 |
Hulin et al | MPT vs MP | Phase III | 229 | 69% vs 39% | CR:7% vs 1% VGPR:22% vs. 7% | OS:45.3 vs. 27.7 PPS:24.1 vs. 19.0 | Blood (ASH Annual Meeting) 2007; 110:75 (abstr) |
Ludwig et al | MPT vs. MP | Phase III | 231 | 68% vs 51% | CR:14% vs. 7% nCR:17% vs.8% VGPR:17% vs. 14% | OS:45 vs. 58 EPS:25 vs. 43 | Blood (ASH Annual Meeting) 2007; 110:529 (abstr) |
Palumbo et al | MPT | Phase I/II | 53 | 81% | CR:23.8% VGPR:47.6% | 1 yr EPS:92% 1 yr OS:100% | J Clin Oncol 2007 |